期刊文献+

外周血单核细胞膜CD14表达预测脓毒症患者预后的研究 被引量:11

The index of membrane CD14 on circulating monocyte is a good predictor for sepsis outcome
原文传递
导出
摘要 目的通过对脓毒症患者外周血单核细胞膜CD14表达的动态观察,探讨CD14表达的动态监测在脓毒症预后预测中的作用。方法对32例成人脓毒症患者外周血单核细胞膜CD14进行动态检测,并与20名健康志愿者进行对照。在脓毒症确诊后的第1天、第3天、第7天及第14天用流式细胞术进行外周血单核细胞膜CD14的检测,采用Cellquest软件分析有核细胞中CD14阳性率(CD14%),CD14平均荧光强度(CD14MFI),同时进行白细胞计数(WBC),并计算CD14指数(CD14IND,CD14%×CD14MFI×WBC)。结果有核细胞中CD14%,CD14MFI,CD14IND明显低于健康对照组。脓毒症患者中死亡组CD14%、CD14MFI、CD14IND均低于存活组。以CD14%≤1.20,CD14MFI≤35.94,CD14IND≤4.40作为脓毒症患者预后预测的临界值,其敏感性和特异性分别为80.0%和90.9%,90.0%和90.9%,90.0%和95.5%。结论外周血单核细胞膜CD14的表达与脓毒症患者预后密切相关。动态监测CD14可预测脓毒症患者的预后。 Objective To find out how to predict the outcome of sepsis with membrane CD14 on circulating monocytes by dynamically monitoring the expression of membrane CD14 on circulating monocytes. Methods A total of 32 adults with sepsis and 20 adult healthy volunteers were included in the study. A double-immunofluorescent whole-blood technique was used to investigate membrane CD14 and HLA-DR expression on the 1 st,3rd ,Sth ,7th,and 14th day after sepsis was confirmed. White blood cell count ( WBC ) was simultaneously performed. Results The mean levels of percentages of CD14-positive cells(CD14% ) ,mean fluorescent intensity of CDI4(CD14MFI) ,CDI4 index(CD14IND,determined as CD14% × CD14MFI× WBC)of the sepsis group were lower than those of health control group, respectively. When CD14% ≤ 1.20, CD14MFI ≤35.94, CD14IND ≤ 4.40 were used as cutoffs to predict the outcome of the patients, sensitivity and specificity were 80. 0% and 90. 9% ,90. 0% and 90. 9% ,90. 0% and 95.5%, respectively. Conclusions CD14%, CD14MFI, CD14IND correlated strongly with the outcome of sepsis patients. Dynamically monitoring the expression of CD14 during the whole septic episode is useful in outcome predicting for sepsis patients.
出处 《中华临床医师杂志(电子版)》 CAS 2012年第8期16-20,共5页 Chinese Journal of Clinicians(Electronic Edition)
关键词 脓毒症 单核细胞 抗原 CD14 预后 Sepsis Monocyte Antigens, CD14 Prognosis
  • 相关文献

参考文献26

  • 1Lekkou A,Karakantza M,Mouzaki A. Cytokine production and monocyte HLA-DR expression as predictors of outcome for patients with community-acquired severe infections[J].Clinical and Diagnostic Laboratory Immunology,2004.161-167.
  • 2Martin GS,Mannino DM,Eaton S. The epidemiology of sepsis in the United States from 1979 through 2000[J].New England Journal of Medicine,2003.1546-1554.
  • 3Angus DC,Linde-Zwirble WT,Lidicker J. Epidemiology of severe sepsis in the United States:analysis of incidence,outcome,and associated costs of care[J].Critical Care Medicine,2001.1303-1310.doi:10.1097/00003246-200107000-00002.
  • 4Sands KE,Bates DW,Lanken PN. Epidemiology of sepsis syndrome in 8 academic medical centers[J].Journal of the American Medical Association,1997.234-240.
  • 5Rangel-Frausto MS,Pitter D,Costigan M. The natural history of the systemic inflammatory response syndrome(SIRS):a prospective study[J].Journal of the American Medical Association,1995.117-123.
  • 6Osuchowski MF,Welch K,Siddiqui J. Circulating Cytokine/Inhibitor Profiles Reshape the Understanding of the SIRS/CARS Continuum in Sepsis and Predict Mortality[J].Journal of Immunology,2006.1967-1974.
  • 7Hotchkiss RS,Karl IE. The Pathophysiology and Treatment of Sepsis[J].New England Journal of Medicine,2003.138-150.
  • 8Reinhart K,Karzai W. Anti-tumor necrosis factor therapy in sepsis:update on clinical trials and lessons learned[J].Critical Care Medicine,2001.121-125.
  • 9Deans KJ,Haley M,Natanson C. Novel therapies for sepsis:a review[J].Journal of Trauma-Injury Infection and Critical Care,2005.867-874.
  • 10Fisher CJ,Dhainaut JF,Opal SM. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome:results from a randomized,double-blind,placebo-controlled trial.Phase Ⅲ rhIL-1ra Sepsis Syndrome Study Group[J].Journal of the American Medical Association,1994.1836-1843.

同被引文献87

引证文献11

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部